HSBC-HOLDINGS-PLC
The 14th annual Expat Explorer study - a global survey of over 20,000 people who live and work abroad - indicates that almost two thirds (65%) of expats feel optimistic about the year ahead despite the volatility of the past 18 months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005540/en/
The key reason driving optimism is their hope to live ‘normally’ again (75%), but six in ten (61%) are also feeling positive because of the quality of life they will be able to enjoy. Expats in Taiwan are the most optimistic (85%), closely followed by those in Australia, New Zealand, and Vietnam (all 83%).
As the world has been in a state of flux during the pandemic, the study suggests that locations where a sense of stability has been maintained ranked highly. Nearly all expats based in Australia, Switzerland, and Jersey (in the Channel Islands) would recommend their location as a ‘stable’ place to live in the next 12 months - Australia (92%), Switzerland (92%), Jersey (90%).
Expats’ desire to live and work abroad has not been diminished by the pandemic – the majority plan to stay in their host location for the foreseeable future, with 80% intending to continue living in their host country for the next year at least, and only 7% planning to move.
The findings suggest expats are prioritising personal lifestyle choices rather than traditional relocation drivers - such as career progression (34%) or expanding professional network (31%). The top five goals that expats look forward to achieving in the next 12 months are:
- Getting to know the local area (50%)
- Travelling (47%)
- Understanding and exploring local culture (47%)
- Making new friends (45%)
- Going out more (41%)
Over two thirds (67%) of expats also believe their quality of life is better in their current location; those based in Indonesia and UAE feel the most fulfilled - 51% say they feel a stronger sense of fulfilment since moving there. Furthermore, globally, over two in five (46%) expats feel that their host communities have changed to be more supportive during the pandemic.
However, the study also highlights some of the challenges that expats have faced during the pandemic. Over half (63%) have been stopped from travelling abroad for business, and the majority (90%) were unable to see family or friends in their home countries. Yet it also points to the resilience of the global expat community, as two in five (42%) say they were able to continue to manage their physical health, and over a third (36%) continued to spend time outside.
Cameron Senior, Interim Head of HSBC Expat, said: "Despite incredibly challenging times, I am encouraged to see sparks of optimism among global expats. Our study confirms that expats continue to thrive in their host countries and many are looking forward to remaining there for the foreseeable future. Following many months of uncertainty, I’m heartened to hear how expats are benefitting from relocating – over two-thirds told us they feel their quality of life is better now, albeit with a lot of changes.
“Despite their positivity, I’m very mindful of the disruption they have experienced (which remains ongoing in certain locations) including their ability to see family or friends in their home countries, and travel for business. This reality puts their optimism in even sharper focus, and makes me more determined to fully support our expat customers as they navigate life away from home.
“So much has changed for global expats but I’m impressed by their resilience and optimism for the future. As the world begins to adjust, HSBC Expat is committed to opening up a world of opportunity for our customers who relocate overseas. We are dedicated to offering support to help them navigate and succeed in an increasingly globalised world.”
The study also shines light on expats’ financial lives, to gauge their financial goals in 2021. Three fifths (60%) wish to save for their retirement, almost a third are looking to build up an emergency savings fund (31%) and saving to purchase a property (30%). Over a fifth (23%) are saving or investing money for their children’s education.
Overall, expats ranked the following locations as the top 10 places to live and work in 2021:
- Switzerland
- Australia
- New Zealand
- UAE
- Guernsey
- Jersey
- Isle of Man
- Bahrain
- Singapore
- Qatar
For more information about the findings, and HSBC Expat products, visit: www.expat.hsbc.com/expat-explorer-results/
-Ends-
Notes to Editors
About Expat Explorer
Expat Explorer is a comprehensive and in-depth global survey of expats. The 2021 survey is HSBC’s broadest look at expat living to date, with expats from 46 countries and territories sharing their views. YouGov surveyed 20,460 adults aged 18+ currently living away from their country of origin/home country, in 143 countries, territories and markets, through an online questionnaire between March and May 2021. A minimum sample of 100 respondents was required for a location to qualify for inclusion; this year, 46 locations qualified.
HSBC Holdings plc
HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customers worldwide from offices in 64 countries and territories in its geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,976bn at 30 June 2021, HSBC is one of the world’s largest banking and financial services organisations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005540/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
